Animal Drugs and Biologics
Their roles in animal health, food safety, and public healthRegulatory Framework, Approval Pathways, and Ongoing Responsibilities
Animal pharmaceuticals and biologics play a critical role in animal health, food safety, and public health. Unlike animal medical devices, animal drugs and biologics are subject to formal FDA premarket review and approval, with defined statutory and regulatory requirements governing their development, manufacture, labeling, and postmarket oversight.
This page provides an overview of how animal drugs and biologics are regulated in the United States, what manufacturers are required to demonstrate, and where regulatory risk most often emerges.
Drugs vs. Biologics: Why the Distinction Matters
While both categories are used to prevent, treat, or diagnose disease in animals, animal drugs and animal biologics are regulated under different statutory authorities and FDA centers.
Animal Drugs
Animal drugs include products that achieve their primary intended purpose through chemical action or that are metabolized by the animal.
Examples include antibiotics and antiparasitics, anti-inflammatory and analgesic drugs, hormones and reproductive products, and sedatives and anesthetics.
Animal drugs are regulated by the FDA Center for Veterinary Medicine (CVM).
Animal Biologics
Animal biologics are products derived from living organisms and are generally used to prevent, diagnose, or treat disease through immunological mechanisms.
Examples include vaccines, bacterins and toxoids, antisera and immunomodulators, and certain diagnostic test kits.
Animal biologics are regulated by the USDA Center for Veterinary Biologics, not FDA.
This division of oversight is a frequent source of confusion for manufacturers and distributors.
Premarket Approval: A Core Difference from Devices
Unlike animal medical devices, animal drugs and biologics require premarket authorization before they can be legally marketed in the United States.
Animal Drug Approval Pathways
Animal drugs typically require approval through one of the following mechanisms: A New Animal Drug Application (NADA), an abbreviated New Animal Drug Application (ANADA) (for generics), conditional Approval (for certain minor species or limited-use scenarios), or indexing (for non–food-producing minor species)
Approval is based on demonstrations of safety (to the animal, user, and food supply where applicable), effectiveness, manufacturing quality and consistency, and accurate labeling and instructions for use.
Animal Biologics Licensing
Animal biologics must be licensed by USDA, with requirements covering product purity, safety, potency, and efficacy, facility inspection and licensing, and lot release and ongoing compliance.
Biologics oversight is often more lot-specific and production-focused than drug regulation.
Manufacturing Oversight and Quality Expectations
Animal pharmaceuticals and biologics are manufactured under explicit quality system requirements, unlike animal devices.
Animal Drug Manufacturing
Animal drug manufacturers must comply with current Good Manufacturing Practice (cGMP) requirements, which govern facility and equipment controls, raw material and component testing, process validation, laboratory controls, stability programs, documentation, and recordkeeping
FDA inspections frequently focus on whether manufacturers can consistently produce drug products that meet approved specifications.
Biologics Manufacturing
Biologics manufacturing is subject to USDA establishment licensing, routine inspection, and often lot release requirements.
Because biologics are inherently variable, regulators expect to see tight control of production processes, robust testing of each lot, and rapid detection of deviations.
Labeling, Claims, and Intended Use
For both animal drugs and biologics, labeling is a regulated component of approval.
Approved labeling defines indications for use, target species, dosage and administration, warnings, precautions, and withdrawal periods (for food animals).
Marketing claims that exceed approved labeling or imply unapproved uses can render a product misbranded or adulterated, even if the formulation itself is unchanged.
Postmarket Surveillance and Reporting Obligations
Approval does not end regulatory responsibility. Manufacturers are expected to monitor product performance after market entry and to act when safety or quality concerns arise.
Key postmarket responsibilities include adverse event reporting, product defect investigations, trend analysis, corrective and preventive actions, and recalls or withdrawals when necessary.
Failure to act promptly once issues are known is a frequent trigger for enforcement action.
Food-Producing Animals and Public Health Considerations
Animal pharmaceuticals used in food-producing species carry additional regulatory weight.
Manufacturers must address drug residues in edible tissues, withdrawal times, human food safety, and environmental impact considerations.
These requirements reflect FDA’s dual role in protecting animal health and the human food supply.
Strategic Implications for Manufacturers
Animal drug and biologics manufacturers operate in a highly structured regulatory environment, but one that still leaves room for risk if quality systems are weak or poorly implemented.
Common risk areas include inadequate investigations, supplier quality failures, stability or potency drift, labeling noncompliance, and delayed recalls.
Strong regulatory and quality systems are not optional. They are foundational.